Novo Undercuts Lilly’s Obesity Drug Price for Cash-Pay in US

10 snips

Nov 17, 2025

Guest

Michael Shah, a Senior Pharma-Biotech Analyst, reveals Novo Nordisk's aggressive pricing strategy for obesity drugs, significantly undercutting Eli Lilly. Liana Baker, Managing Editor for Deals, shares insights on the $6.2 billion acquisition of Sealed Air by Clayton, Dubilier & Rice. Mary Ross Gilbert discusses how retail giants like Ralph Lauren and Gap are poised for a strong sales boost in 2026, while Michael Halen analyzes restaurant trends and how quick-service chains are adapting to rising costs and changing customer preferences.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

Price Cuts Can Rapidly Expand GLP-1 Use

U.S. GLP-1 penetration is low but highly price sensitive, so lower prices will accelerate adoption.
The White House pilot could unlock 7–8 million Medicare patients and widen access in 2026–27.

INSIGHT

Compounded GLP-1 Users Face Headwinds

About 1.2 million U.S. patients use compounded GLP-1 formulations today.
Shah says cheaper branded pricing will narrow the gap and hurt compounding players.

INSIGHT

Obesity Drugs Drive Pharma M&A Interest

Large pharma pursues obesity assets to tap a huge, underpenetrated market and offset patent cliffs.
Shah cites many GLP-1 and other obesity programs drawing M&A and deal activity.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

Watch Scarlet and Paul LIVE every day on YouTube: http://bit.ly/3vTiACF.

Bloomberg Intelligence hosted by Paul Sweeney and Scarlet Fu

- Michael Shah, Bloomberg Intelligence Senior Pharma-Biotech Analyst, discusses Novo Nordisk undercutting Eli Lilly & Co. on obesity drugs for cash-pay patients, with introductory doses of Wegovy and Ozempic available for $199 a month. After the first two months, Novo will offer the drugs for $349 a month, 30% less than the current self-pay price, matching Lilly’s price for a low dose of Zepbound.

-- Liana Baker, Bloomberg News Managing Editor for Deals, discusses Clayton Dubilier & Rice agreeing to buy Sealed Air Corp. in a deal valuing the packaging company that invented Bubble Wrap at $6.2 billion. The private equity firm will pay $42.15 a share for Charlotte, North Carolina-based Sealed Air, according to a statement Monday. That’s slightly below Friday’s closing price of $43.28 a share, after reports that CD&R was weighing a takeover.

-Mary Ross Gilbert, Bloomberg Intelligence, Senior Equity Analyst, Covering Retail, discusses why Ralph Lauren, Gap, Macy's and Dillard's are set to post stronger full-price sales in 2026 as fresh styles, collaborations and limited editions gain traction on social media, while new store openings can lift Aritzia, Burlington and Urban Outfitters. According to Bloomberg Intelligence: Tariff pressures should ease by 2H26, with selective price hikes and other measures poised to boost margins across most retailers.

-Michael Halen, Bloomberg Intelligence Senior Restaurant and Foodservice Analyst discusses his outlook for U.S restaurant sales in the fourth quarter. According to Bloomberg Intelligence: US restaurant same-store sales rose 0.7% in October, but could drop in November due to the government shutdown and a tough comparison. Time is running out on casual dining's edge over quick service as it faces steep base effects this month and in 2026. Quick-service chains like McDonald's and Domino's should outperform on easier comparisons, value and a bigger benefit from tax reform.

See omnystudio.com/listener for privacy information.